Your browser is no longer supported. Please, upgrade your browser.
EIDX Eidos Therapeutics, Inc. weekly Stock Chart
EIDX [NASD]
Eidos Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own1.20% Shs Outstand44.30M Perf Week-6.08%
Market Cap1.86B Forward P/E- EPS next Y-2.56 Insider Trans- Shs Float12.25M Perf Month-14.24%
Income-37.80M PEG- EPS next Q-0.54 Inst Own32.40% Short Float17.09% Perf Quarter-29.67%
Sales26.70M P/S69.72 EPS this Y44.60% Inst Trans5.13% Short Ratio17.12 Perf Half Y11.46%
Book/sh4.58 P/B9.17 EPS next Y-9.40% ROA-22.40% Target Price60.43 Perf Year82.46%
Cash/sh4.32 P/C9.74 EPS next 5Y28.00% ROE-24.70% 52W Range21.44 - 66.56 Perf YTD-26.78%
Dividend- P/FCF- EPS past 5Y- ROI-21.60% 52W High-36.87% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin90.60% 52W Low95.99% ATR5.64
Employees45 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)43.74 Volatility15.21% 13.45%
OptionableNo Debt/Eq0.09 EPS Q/Q-87.20% Profit Margin- Rel Volume0.98 Prev Close48.34
ShortableYes LT Debt/Eq0.09 Earnings- Payout- Avg Volume122.30K Price42.02
Recom1.90 SMA20-8.30% SMA50-16.38% SMA200-7.35% Volume119,329 Change-13.07%
Feb-20-20Initiated Guggenheim Buy $66
Feb-18-20Downgrade Barclays Equal Weight → Underweight $45
Nov-01-19Downgrade Barclays Overweight → Equal Weight $37 → $45
Jul-22-19Initiated Piper Jaffray Overweight $55
Feb-27-19Upgrade JP Morgan Neutral → Overweight
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Oct-31-18Initiated ROTH Capital Buy
Jul-16-18Initiated JP Morgan Overweight $36
Jul-16-18Initiated BofA/Merrill Neutral $24
Jul-16-18Initiated Barclays Overweight $32
Mar-19-20 10:29AM  Why Eidos Therapeutics (EIDX) Stock Might be a Great Pick Zacks +15.22%
Feb-26-20 04:30PM  Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update GlobeNewswire
Feb-05-20 09:15AM  Vertex (VRTX) Hits 52-Week High, Can the Run Continue? Zacks
Dec-12-19 03:14PM  Eidos Therapeutics, Inc. (EIDX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-06-19 08:00AM  12 Biotech Stocks Primed For A Short Squeeze Benzinga
Nov-18-19 09:00AM  Eidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the Upgrade Zacks +18.20%
Nov-16-19 07:28PM  CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures GlobeNewswire
05:30PM  BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures GlobeNewswire
Oct-31-19 04:30PM  Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire
Oct-28-19 05:14PM  Hedge Funds Are Buying Eidos Therapeutics, Inc. (EIDX) Insider Monkey
Oct-21-19 05:22PM  How this company is disrupting biotech with 30-somethings and industry vets American City Business Journals +8.54%
Oct-14-19 07:30AM  BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics Business Wire
Oct-11-19 09:27AM  Alexion (ALXN) Collaborates With Stealth BioTherapeutics Zacks
Sep-30-19 07:00AM  Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation GlobeNewswire
Sep-19-19 08:00AM  Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire -10.66%
07:17AM  Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019 Zacks
Sep-16-19 08:03AM  EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Business Wire
Sep-12-19 06:50PM  Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares Business Wire
Sep-10-19 11:39AM  Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan Zacks
Sep-03-19 12:15PM  Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm EIDX GlobeNewswire
Aug-29-19 09:16PM  3 New Biotech Stocks That Keep On Soaring Motley Fool -6.33%
Aug-16-19 04:22PM  Andreas Halvorsen's Top 5 Buys of the 2nd Quarter GuruFocus.com
Aug-14-19 08:00AM  Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. - EIDX ACCESSWIRE
Aug-12-19 04:42PM  Little over year after IPO, biotech's majority owner wants to buy it all American City Business Journals +6.11%
08:25AM  Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares Business Wire
Aug-09-19 07:19AM  The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2 Benzinga +9.70%
Aug-01-19 04:30PM  Eidos Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire +6.60%
Jul-15-19 07:11AM  3 Stocks Corporate Insiders are Buying Now TipRanks
Jul-01-19 06:02AM  Is Eidos Therapeutics, Inc. (NASDAQ:EIDX) Trading At A 34% Discount? Simply Wall St.
06:00AM  Are Investors Undervaluing Eidos Therapeutics, Inc. (NASDAQ:EIDX) By 34%? Simply Wall St.
Jun-18-19 08:00AM  Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-03-19 12:45PM  Weekly CEO Buys Highlight GuruFocus.com
May-30-19 07:12PM  Gene Therapy Parent BridgeBio Set to Go Public GuruFocus.com
May-27-19 01:24AM  3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million American City Business Journals
May-09-19 07:59PM  Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ? Insider Monkey
May-07-19 08:21PM  Can Pfizer Leap Over the Competition With This Potential Blockbuster? Motley Fool
04:30PM  Eidos Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-19-19 08:00AM  Eidos Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Apr-15-19 08:30AM  Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results GlobeNewswire
Apr-05-19 03:40PM  RM LAW Announces an Investigation of Eidos Therapeutics, Inc. PR Newswire
09:56AM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Apr-03-19 04:20PM  Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Eidos Therapeutics, Inc. (EIDX) Investigation ACCESSWIRE
Apr-02-19 12:22PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Apr-01-19 09:54PM  Bragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the Firm GlobeNewswire
08:59PM  INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
07:59PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. EIDX Business Wire
06:34PM  Eidos Therapeutics Investigated by Block & Leviton LLP For Violations of Federal Securities Laws GlobeNewswire
Mar-18-19 09:30AM  Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions GlobeNewswire
Mar-11-19 08:00AM  Eidos Therapeutics to Present at 31st Annual ROTH Conference GlobeNewswire
Mar-04-19 09:19AM  Can This Biotech Puppy Run With the Big Dogs? Motley Fool +9.00%
Feb-27-19 07:00AM  Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint GlobeNewswire +10.34%
Feb-25-19 08:00AM  Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design GlobeNewswire
Feb-21-19 08:00AM  Eidos Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Jan-23-19 06:02PM  [$$] Drug Developer BridgeBio Raises $299 Million in Fresh Funding The Wall Street Journal
Jan-02-19 01:15PM  Here are the winners and losers from Bay Area's IPO class of 2018 American City Business Journals
08:00AM  Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-20-18 10:39PM  Is Eidos Therapeutics, Inc. (EIDX) A Good Stock To Buy? Insider Monkey
Dec-06-18 04:15PM  Eidos Therapeutics Appoints William Lis to Board of Directors GlobeNewswire
Dec-05-18 10:35AM  This year's Bay Area IPO batch remains up 44% despite market turbulence American City Business Journals
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-21-18 08:15AM  Factors of Influence in 2018, Key Indicators and Opportunity within Okta, One Horizon Group, Vivopower International Plc, PetIQ, Quanterix, and Eidos Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Nov-14-18 08:00AM  Eidos Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-10-18 10:00AM  Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy GlobeNewswire
Nov-06-18 04:05PM  Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-29-18 08:00AM  Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results GlobeNewswire
Oct-26-18 08:00AM  Eidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin Amyloidosis GlobeNewswire
Oct-05-18 09:10AM  Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation GlobeNewswire +9.56%
Oct-03-18 02:35PM  FDA Grants Orphan Drug Designation to Eidos Therapeutics Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis GlobeNewswire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals
Sep-25-18 08:00AM  Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire -5.32%
Sep-17-18 08:00AM  Eidos Therapeutics Presents Data from its Phase 1 Clinical Trial of AG10 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America GlobeNewswire
Aug-28-18 08:13AM  The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic Benzinga
Aug-27-18 02:59PM  Pfizer Slips Despite Mostly Positive Tafamidis Data; 4 Pharma Stocks Make Sympathy Moves Benzinga -31.09%
Aug-23-18 08:00AM  Eidos Therapeutics Announces Publication of AG10 Molecular Design in Journal of Medicinal Chemistry GlobeNewswire +9.85%
Aug-07-18 04:30PM  Eidos Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-13-18 02:45PM  Here are Q2's 10 biggest VC-backed exits from the Bay Area American City Business Journals
Jun-28-18 09:07AM  Pair of upsized Bay Area biotech IPOs head in opposite directions after raising $335M American City Business Journals
Jun-25-18 02:37PM  The Funded: More biotech IPOs highlight Bay Area venture news this week, along with a new Jay Z VC fund American City Business Journals -7.31%
Jun-22-18 04:05PM  Eidos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-20-18 03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
10:52AM  Eidos Therapeutics stock soars in debut MarketWatch
10:52AM  Eidos Therapeutics stock soars in debut MarketWatch
Jun-19-18 10:49PM  Eidos Therapeutics Announces Pricing of Initial Public Offering PR Newswire
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.